Speaking at InformaConnect’s #Copay2024, Kevin Herwig gave a policy update on developments related to copay accumulators, maximizers, and alternative funding programs and the failure of HHS to enforce the HIV+Hepatitis Policy Institute’s Court victory a year ago or fully close the loophole allowing insurers to designate prescription drugs as non-essential health benefits.
HIV+Hepatitis Policy Institute will convene a panel on Friday, April 19, 2024, at the Biomedical HIV Prevention Summit to examine how PrEP is provided today by entities including community health centers, CBOs, pharmacies, telemedicine platforms, and state health departments. We will examine how this work is financed by leveraging existing programs and systems, as well as current barriers and what can be done to close PrEP access gaps in underserved populations.
Carl Schmid and Kevin Herwig offer updates at USCHA on Braidwood v Becerra, which challenges ACA’s preventive services coverage requirement, and discuss the amicus brief filed by HIV+Hepatitis Policy Institute and supported by 24 HIV and hepatitis organizations and other amici briefs filed by other groups.
Carl Schmid of the HIV+Hepatitis Policy Institute joins Hannah Lynch, Associate Director, U.S. Public Policy at UCB, to discuss how we can evolve the healthcare system to better serve people living with severe diseases and help them overcome access barriers.
Carl Schmid participates in the “Prescription for Better Access” podcast with Lauren Crawford Shaver and hosts Mark Hansan and Dr. Scott Howell to examine how PBM copay accumulator and maximizer policies harm patients by not counting copay assistance toward patient out-of-pocket costs and deductibles, and what can be done to keep prescription drugs accessible and affordable.